teclistamab
genmab,janssen
['majestec-1', 'teclistamab', 'mmsm']
majestec-1 results presented by teclistamab
orr 63%; mrd negativity rate 27%
mpfs 11.3 months
just published in nejm
#mmsm #asco2022 
Oncologist and researcher on Myeloma service @mskcancercenter Interested in nutrition ?? for cancer and immune therapies. Views are my own